MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
13 févr. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
10 févr. 2020 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 10, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Present at the J.P. Morgan Healthcare Conference
13 janv. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Outlines Corporate Priorities for 2020
09 janv. 2020 16h30 HE
|
MacroGenics, Inc.
Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
19 déc. 2019 12h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
11 déc. 2019 10h00 HE
|
MacroGenics, Inc.
Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
09 déc. 2019 15h05 HE
|
MacroGenics, Inc.
Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in the Evercore ISI HealthCONx Conference
02 déc. 2019 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
07 nov. 2019 16h45 HE
|
MacroGenics, Inc.
Rockville, MD, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
06 nov. 2019 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...